Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry [Phase 1]

View source ↗

Summary

A Phase 1 study to assess safety, tolerability, pharmacokinetics and immunogenicity of a single dose of Efimosfermin Alfa in healthy participants of Chinese, Ja…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Efimosfermin Alfa (efimosfermin alfa)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Non-alcoholic Fatty Liver Disease | Phase 1 | Status: RECRUITING